Clinical Trial Update: 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 177Lu-DOTA-octreotate therapy in neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTA-Octreotate (177Lu-DOTA-Octreotate)

Snippet

Sponsor: Ebrahim S Delpassand | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED